Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study.
Dermatology Unit, Department of Medicine, University of Padua, Via Cesare Battisti 206, IT-35128 Padua, Italy. stefano.piaserico@unipd.it.
Stefano
S
Piaserico
Paolo
P
Gisondi
Clara
C
De Simone
Elena
E
Marinello
Andrea
A
Conti
Paolo
P
Amerio
Andrea
A
Peserico
D000068879:Adalimumab / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000068800:Etanercept / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007558:Italy; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology
D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D000068800:Etanercept